Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
48
BBIO Quote, Financials, Valuation and Earnings
Last price:
$76.33
Seasonality move
:
-13.18%
Day range:
$74.20 - $77.20
52-week range:
$26.02 - $77.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
41.08x
P/B ratio:
--
Volume:
4.7M
Avg. volume:
2.1M
1-year change:
191.11%
Market cap:
$14.7B
Revenue:
$221.9M
EPS (TTM):
-$4.19
Analysts' Opinion
-
Consensus RatingBridgeBio Pharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $85.78, BridgeBio Pharma, Inc. has an estimated upside of 12.42% from its current price of $76.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $76.30.
Fair Value
-
According to the consensus of 16 analysts, BridgeBio Pharma, Inc. has 12.42% upside to fair value with a price target of $85.78 per share.
BBIO vs. S&P 500
-
Over the past 5 trading days, BridgeBio Pharma, Inc. has overperformed the S&P 500 by 1.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BridgeBio Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BridgeBio Pharma, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter BridgeBio Pharma, Inc. reported revenues of $120.7M.
Earnings Growth
-
BridgeBio Pharma, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter BridgeBio Pharma, Inc. reported earnings per share of -$0.95.
Enterprise value:
16.8B
EV / Invested capital:
--
Price / LTM sales:
41.08x
EV / EBIT:
--
EV / Revenue:
47.41x
PEG ratio (5yr expected):
-0.25x
EV / Free cash flow:
-28.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$336.1M
Return On Assets:
-88.65%
Net Income Margin (TTM):
-227.74%
Return On Equity:
--
Return On Invested Capital:
-109.98%
Operating Margin:
-112.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $9.4M | $217.8M | $353.8M | $2.7M | $120.7M | |
| Gross Profit | $2.2M | $210.3M | $336.1M | $896K | $113.4M | |
| Operating Income | -$544.3M | -$532.7M | -$595M | -$187.1M | -$136.4M | |
| EBITDA | -$537.8M | -$526.4M | -$589.6M | -$185.6M | -$135M | |
| Diluted EPS | -$3.91 | -$2.41 | -$4.19 | -$0.86 | -$0.95 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $639.7M | $642.2M | $587.7M | $444.6M | $839.4M | |
| Total Assets | $781.5M | $728.7M | $655M | $665M | $998.3M | |
| Current Liabilities | $95.8M | $119.2M | $106.1M | $139.2M | $216.6M | |
| Total Liabilities | $1.5B | $1.9B | $1.8B | $1.9B | $2.9B | |
| Total Equity | -$735.9M | -$1.1B | -$1.2B | -$1.2B | -$1.9B | |
| Total Debt | $1.4B | $1.7B | $1.7B | $1.7B | $2.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$495M | -$450.2M | -$584.8M | -$180.6M | -$109.6M | |
| Cash From Investing | $72.1M | $64M | -$11.8M | $38.2M | $4.5M | |
| Cash From Financing | $461.3M | $270M | $833.9M | $707K | -$894K | |
| Free Cash Flow | -$496.7M | -$456.3M | -$597.6M | -$182.3M | -$112.4M | |
BBIO
Sector
Market Cap
$14.7B
$27.9M
Price % of 52-Week High
98.83%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-1.77%
-1.49%
1-Year Price Total Return
191.11%
-16.66%
Beta (5-Year)
1.256
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$74.57
200-day SMA
Buy
Level
$48.11
Bollinger Bands (100)
Buy
Level
49.15 - 67.47
Chaikin Money Flow
Buy
Level
42.4M
20-day SMA
Buy
Level
$73.09
Relative Strength Index (RSI14)
Buy
Level
66.51
ADX Line
Buy
Level
41.28
Williams %R
Sell
Level
-13.1387
50-day SMA
Buy
Level
$65.78
MACD (12, 26)
Buy
Level
2.71
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
206.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4907)
Sell
CA Score
(Annual)
Level (-15.0343)
Sell
Beneish M-Score
(Annual)
Level (16.6697)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (14.6831)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Stock Forecast FAQ
In the current month, BBIO has received 15 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BBIO average analyst price target in the past 3 months is $85.78.
-
Where Will BridgeBio Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BridgeBio Pharma, Inc. share price will rise to $85.78 per share over the next 12 months.
-
What Do Analysts Say About BridgeBio Pharma, Inc.?
Analysts are divided on their view about BridgeBio Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BridgeBio Pharma, Inc. is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is BridgeBio Pharma, Inc.'s Price Target?
The price target for BridgeBio Pharma, Inc. over the next 1-year time period is forecast to be $85.78 according to 16 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BridgeBio Pharma, Inc. is a Buy. 15 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BBIO?
You can purchase shares of BridgeBio Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BridgeBio Pharma, Inc. shares.
-
What Is The BridgeBio Pharma, Inc. Share Price Today?
BridgeBio Pharma, Inc. was last trading at $76.33 per share. This represents the most recent stock quote for BridgeBio Pharma, Inc.. Yesterday, BridgeBio Pharma, Inc. closed at $76.30 per share.
-
How To Buy BridgeBio Pharma, Inc. Stock Online?
In order to purchase BridgeBio Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BBIO
Sector
P/E ratio
--
23.85x
PEG ratio
-0.25x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
41.08x
1.58x
Growth Metrics
BBIO
Sector
Revenue growth
4318.01%
4.62%
Earnings growth
-10.81%
10.5%
Revenue (5-year growth)
40.48%
6.5%
Earnings forecast
-$0.60
-$0.21
Profitability
BBIO
Sector
Profitability FY 2024
$214.3M
$3.6M
Return on invested capital
-109.98%
-31.87%
Return on assets
-88.65%
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Jan
28
Balance Sheet
BBIO
Sector
Total cash
$646.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$919.3M
$76.9M
Long term debt
$2.7B
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
